Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier

被引:34
作者
Pathan, Nazneen [1 ]
Shende, Pravin [1 ]
机构
[1] SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, VL Mehta Rd, Mumbai, Maharashtra, India
关键词
P-glycoprotein; Blood-brain-barrier; CNS disorders; Nanoformulations; IN-VIVO EVIDENCE; DRUG-DELIVERY; STEM-CELLS; MODULATION; EFFLUX; NANOPARTICLES; EXPRESSION; VITRO; INHIBITORS; CNS;
D O I
10.1016/j.jconrel.2021.05.046
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
P-Glycoprotein serves as a gatekeeper in the blood-brain-barrier wherein, it shows a vital part in the elimination of xenobiotics, drugs, foreign molecules etc. and guards the central nervous system from infections and external toxic molecules by functioning as an efflux transporter. It plays an essential role in various brain-related conditions like Parkinsonism, Alzheimer's disease, depression, cancer, etc. and terminates the entry of therapeutic agents across blood-brain-barrier which remains a significant challenge serving as major hindrance in pharmacotherapy of disease. The physiological structure and topology of P-glycoprotein and its relation with bloodbrain-barrier and central nervous system gives an idea for targeting nanocarriers across the barrier into brain. This review article provides an overview of current understanding of the nanoformulations-based P-gp trafficking strategies like nanocarriers, stem cell therapy, drugs, substrates, polymeric materials, chemical compounds as well as naturally occurring active constituents for improving drug transport in brain across blood-brain-barrier and contributing in effective nanotherapeutic development for treatment of CNS disorders.
引用
收藏
页码:398 / 407
页数:10
相关论文
共 87 条
[1]   Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery? [J].
Abdullahi, Wazir ;
Davis, Thomas P. ;
Ronaldson, Patrick T. .
AAPS JOURNAL, 2017, 19 (04) :931-939
[2]   Doxycycline as an inhibitor of p-glycoprotein in the alpaca for the purpose of maintaining avermectins in the CNS during treatment for parelaphostrongylosis [J].
Agbedanu, Prince N. ;
Anderson, Kristi L. ;
Brewer, Matthew T. ;
Carlson, Steve A. .
VETERINARY PARASITOLOGY, 2015, 212 (3-4) :303-307
[3]   The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review [J].
Akhtar, Naseem ;
Ahad, Abdul ;
Khar, Roop Kishan ;
Jaggi, Manu ;
Aqil, Mohammed ;
Iqbal, Zeenat ;
Ahmad, Farhan Jalees ;
Talegaonkar, Sushama .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (04) :561-576
[4]  
Amir T., 2008, BONE, V23, P1, DOI [DOI 10.1124/PR.107.07109, 10.1124/pr.107.07109]
[5]   Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease [J].
Bartels, A. L. .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (26) :2771-2777
[6]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
[7]  
Bharate J.B., 2015, BIOMOL CHEM, DOI [10.1039/c5ob00554j, DOI 10.1039/C5OB00554J]
[8]  
Bloise E, 2019, MULTIDRUG RESISTANCE, DOI [10.1016/B978-0-12-813146-6.00019-9, DOI 10.1016/B978-0-12-813146-6.00019-9]
[9]   Neural stem cell therapy for neurovascular injury in Alzheimer's disease [J].
Boese, Austin C. ;
Hamblin, Milton H. ;
Lee, Jean-Pyo .
EXPERIMENTAL NEUROLOGY, 2020, 324
[10]   Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood-Brain Barrier [J].
Bohn, Kelsey ;
Lange, Allison ;
Chmielewski, Jean ;
Hrycyna, Christine A. .
MOLECULAR PHARMACEUTICS, 2017, 14 (04) :1107-1119